10 research outputs found
The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, ILWOS: 000318009801095…Amer Soc Clin Onco
Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study
Kaplan, Muhammet Ali/0000-0003-0882-0524; SAKIN, Abdullah/0000-0003-2538-8569WOS: 000489996700003PubMed: 31437835Background: Colorectal cancer (CRC) is a rare disease amongst children and adolescents. Previous studies have reported a number of differences between children/adolescents, young adults, and adult patients with CRC. However, none of these studies compared these age groups according to their clinicopathologic and prognostic characteristics. in the current study, we compare these three age groups. Methods:A total of 173 (1.1% of 15,654 patients) young CRC patients (25 years) were also included. Patients were divided into three age groups: child/adolescent (10-19 years), young adult (20-25 years), and adult (>25 years). Results: Statistical differences amongst the three groups in terms of gender (p = 0.446), family history (p = 0.578), symptoms of presentation (p = 0.306), and interval between initiation of symptoms and diagnosis (p = 0.710) could not be demonstrated. Whilst abdominal pain (p < 0.001) and vomiting (p = 0.002) were less common in young adults than in other groups, rectal bleeding and changes in bowel habits were relatively less common in adolescents than in other groups. Rectal localisation (p = 0.035), mucinous adenocarcinoma (p < 0.001), and a poorly differentiated histologic subtype (p < 0.001) were less common in the adult group than in other groups. the percentage of patients with metastasis and sites of metastasis (e.g., peritoneum and lung) differed between groups. the median overall survival was 32.6 months in the adolescent group, 57.8 months in the young adult group and was not reached in the adult group (p = 0.022). the median event-free survival of the adolescent, young adult, and adult groups was 29.0, 29.9, and 61.6 months, respectively (p = 0.003). Conclusions: CRC patients of different age groups present different clinicopathologic and prognostic characteristics. Clinicians should be aware of and manage the disease according to these differences
Uptake Patterns of Untreated Primary Gastrointestinal Extranodal Lymphomas on Initial Staging F-18-FDG PET/CT and Metabolic Tumor Parameters
Objective: Non-Hodgkin's lymphomas arising from tissues other than primary lymphatic sites are classified as primary extranodal lymphomas (PEL). PELs of the gastrointestinal system (PGISL) originate from the lymphatic tissues within the gastrointestinal tract. The prognostic value of F-18-FDG PET/CT in lymphomas is high in terms of both overall survival (OS) and disease-free survival (DFS). Our aim was to investigate the uptake patterns and properties of low-grade and high-grade PGISL on primary staging F-18-FDG PET/CT, as well as the prognostic significance of metabolic tumor parameters in high grade PGISL
Assessment of the efficiency of Brentuximab Vedotin in patients with pulmonary Hodgkin Lymphoma by the mean of neutrophil to lymphocyte ratio
Background: Lung involvement, an uncommon initial presentation of Hodgkin Lymphoma (HL), may appear as primary or secondary pulmonary HL. Although the combination of Brentuximab vedotin (BV) with AVD is suggested as an alternative treatment to combinations including bleomycin for patients with pulmonary involvement. The efficacy and adverse effects of BV have not been specialized on pulmonary HL. There is insufficient data about neutrophil to lymphocyte ratio (NLR) of cases treated with BV. We performed this retrospective study to evaluate the efficacy and toxicity of BV in patients with pulmonary HL and to demonstrate the prognostic role of NLR in patients treated with BV. Methods: Data of 10 CD 30 (+) HL patients who treated with BV between years 2011–2016 were analyzed retrospectively. Relapsed cases after autologous bone marrow transplantation (ABMT) and/or resistant cases to at least two lines of chemotherapy, and treated with BV were included in the study. Results: Patients underwent a median of 8.5 cycles BV. Eight patients (80%) achieved an objective response including 2 of them (20%) with complete response and six of them (60%) with a partial response at the end of the 3rd cycle. At a median follow-up of 16.8 months, median progression-free survival for all patients was 6 months and 3 patients died because of progression. BV, as a single agent, revealed well response in HL cases with pulmonary involvement and other clinical types. No pulmonary toxicity has been occurred due to BV. NLR was found to be o good indicator of prognosis and mortality in pulmonary HL patients and other HL patients. While NLR was not influenced by BV, it can be suggested as an easy prognostic marker in patients treated with BV. Conclusion: BV may be used as a bridge therapy to the next curative treatment in order to obtain minimal tumor burden in pulmonary HL patients, and NLR can be used as a prognostic marker in these patients. We believe that this study contributes the current literature in terms of being the first research on the referred issue. Keywords: Brentuximab vedotin, Hodgkin lymphoma, Pulmonary infiltratio
Comparison of the clinical features and hematopoietic stem cell transplantation outcomes of mediastinal malignant germ cell tumors with nonmediastinal extragonadal placements.
Even though the primary mediastinal extragonadal germ cell tumors (EGCTs) are rare, they are noteworthy in the differential diagnosis of mediastinal masses. In this study, we aimed to identify the clinical features of mediastinal malignant GCTs and compare the results of hematopoietic stem cell transplantation between mediastinal and nonmediastinal malignant EGCTs
Comparison of the clinical features and hematopoietic stem cell transplantation outcomes of mediastinal malignant germ cell tumors with nonmediastinal extragonadal placements
Objective: Even though the primary mediastinal extragonadal germ cell
tumors (EGCTs) are rare, they are noteworthy in the differential
diagnosis of mediastinal masses. In this study, we aimed to identify the
clinical features of mediastinal malignant GCTs and compare the results
of hematopoietic stem cell transplantation between mediastinal and
nonmediastinal malignant EGCTs.
Method: Data of the patients with EGCT who were treated and underwent
hematopoietic stem cell transplantation at our hospital between 1988 and
2015 were retrieved retrospectively. Results were compared between
mediastinal and nonmediastinal EGCTs.
Results: Data of 65 patients diagnosed with EGCT (37 {[}56.92\%] cases
with mediastinal EGCT and 28 {[}43.07\%] cases with nonmediastinal EGCT)
were assessed. The clinical stages, frequency of pretransplant status,
mean pretransplant time, and mean number of chemotherapy lines before
hematopoietic stem cell transplantation were not significantly different
between groups. Although the overall survival did not significantly
differ between groups, the 5-year survival was significantly higher in
mediastinal EGCTs (P= 0.02). Yolk sac tumor was significantly more
common in mediastinal EGCTs (P= 0.05). Mortality rates were higher in
seminomas and yolk sac tumors in all cases, higher in embryonal
carcinomas in mediastinal EGCT group and higher in yolk sac tumors in
nonmediastinal EGCT group. While choriocarcinomas had more aggressive
courses in mediastinal EGCTs, seminomas and yolk sac tumors had poorer
prognosis in nonmediastinal EGCTs. Short pretransplant time and
persistence of elevated posttransplant beta hCG and AFP levels were the
significant mortality risk factors both in mediastinal and
nonmediastinal EGCTs.
Conclusion: Mediastinal placement of EGCT was not a poor prognostic
factor; furthermore, the 5-year survival was significantly higher in
mediastinal EGCTs. According to our knowledge, this is the first study
that compares the clinical outcomes of hematopoietic stem cell
transplantation of mediastinal and nonmediastinal malignant EGCTs